Birt-Hogg-Dubé syndrome is a rare, inherited condition that mainly affects the skin, lungs, and kidneys. It happens because of a change (pathogenic variant) in a gene called FLCN (folliculin). People with BHD often develop small, harmless skin bumps on the face, neck, and upper chest. Many also have air-filled cysts in the lungs that can lead to a collapsed lung (pneumothorax). Over a lifetime, there is also an increased chance of getting kidney tumors, which can be benign or malignant. The condition is autosomal dominant, which means a parent with BHD has a 1 in 2 (50%) chance of passing it to a child. Early recognition and regular kidney imaging help reduce serious problems. NCBI+2Cancer.gov+2
Birt–Hogg–Dubé syndrome is a rare, inherited condition caused by harmful changes (pathogenic variants) in a tumor-suppressor gene called FLCN. People with BHD often develop small skin bumps (called fibrofolliculomas), multiple cysts in the lungs that can lead to spontaneous pneumothorax (collapsed lung), and a higher lifetime risk of certain kidney tumors (often chromophobe renal cell carcinoma, hybrid oncocytic tumors, oncocytoma). The condition is autosomal dominant—one changed copy of the gene is enough to cause risk—and its severity varies widely even inside the same family. Diagnosis usually combines clinical signs with genetic testing, and long-term kidney imaging surveillance is recommended in adults. NCBI+1
Why BHD happens
The FLCN (folliculin) protein helps cells sense nutrients and balance key growth and energy pathways (mTOR, AMPK, HIF-1α signaling). When FLCN does not work properly, cells may grow or survive when they should not, and this can promote kidney tumor development and formation of lung cysts and skin hamartomas. Research shows FLCN interacts with FNIP1/2 and Rag GTPases and can influence glycolysis through LDHA, helping explain the kidney-tumor tendency in BHD. Genomics Education Programme+3PMC+3Frontiers+3
Other names
Birt-Hogg-Dubé syndrome may also be called: BHD syndrome; Hornstein-Knickenberg syndrome (older term used for similar skin lesions); fibrofolliculoma syndrome; FLCN-related syndrome; folliculin tumor-predisposition syndrome. These names all point to the same core disorder caused by changes in FLCN. NCBI+1
The FLCN gene makes a protein called folliculin, which helps cells sense nutrients and control growth pathways (including AMPK–mTOR signaling). When FLCN does not work, tiny hair-follicle structures in the skin grow into small bumps, lung tissue forms cysts that can burst, and kidney cells can form tumors. BHD is variable: even within one family, skin, lung, and kidney features can differ a lot. PMC+1
Types
BHD is one genetic condition, but clinicians often talk about it by dominant organ features. Thinking about “types” this way helps tailor checkups:
Skin-predominant BHD — many fibrofolliculomas (tiny, firm, white to skin-colored bumps) on face/neck/upper trunk; sometimes trichodiscomas and acrochordons (skin tags). NCBI+1
Lung-predominant BHD — multiple lung cysts (often in the lower parts of the lungs) with a higher risk of spontaneous pneumothorax (collapsed lung), sometimes the first sign in a young adult. Cancer.gov+1
Kidney-predominant BHD — increased lifetime risk of renal cell carcinoma and other renal tumors (often multiple and on both sides). Hybrid oncocytic/chromophobe tumors are classic, but other types occur. PubMed+1
Mixed-organ BHD — common in practice; people have combinations of the above to different degrees, even within the same family. NCBI
Causes
BHD itself has one root cause: a pathogenic variant in FLCN. The items below explain why features appear or worsen, who is at risk, and what can trigger events like lung collapse. Each is written in simple language.
FLCN pathogenic variant (inherited) — the main cause; one altered copy is enough to cause BHD. NCBI
De novo FLCN variant — sometimes a person is the first in the family to have it. PubMed
Family history — a parent, sibling, or child with BHD raises risk by 50% per pregnancy. PubMed
Tumor-suppressor loss in kidney cells — second “hit” events in kidney cells can drive tumor growth. PMC
Abnormal mTOR/AMPK signaling — mis-signaling promotes skin bumps and kidney tumor biology. PMC
Lung cyst formation — structural weakness in lung tissue leads to cysts that may pop. Cancer.gov
Physical strain/pressure changes — sudden pressure shifts can precipitate pneumothorax in cystic lungs. Cancer.gov
Air travel / altitude change — cabin pressure shifts may increase pneumothorax risk in people with large cysts. PMC
Smoking — not a cause of BHD, but may worsen lung health and pneumothorax risk. PMC
Early adulthood — many signs appear after the teen years into adulthood, so risk shows up with age. Cancer.gov
Male sex (for skin lesions) — some series report more visible facial bumps in men, but both sexes are affected. NCBI
Multiple kidney tumors over time — risk accumulates with age without surveillance. Cancer.gov
Radiation exposure — not a cause of BHD, but repeated CT radiation is avoided; MRI is preferred for surveillance. genturis.eu
Certain FLCN variant types — truncating vs. other variants are all disease-causing; genotype–phenotype links are still being studied. Cancer.gov
Cutaneous hair-follicle growth signals — drive formation of fibrofolliculomas. PMC
Renal oncocytic pathways — favor hybrid and chromophobe-like tumors in BHD. PubMed
Lung base-predominant cyst distribution — an anatomic pattern that helps explain pneumothorax risk. Cancer.gov
Under-recognition — missed diagnosis delays surveillance, allowing tumors to grow unnoticed. Cancer.gov
Lack of family testing — relatives who are not tested may miss early, protective screening. PubMed
Comorbid lung disease — other lung problems can compound breathlessness and collapse risk. Cancer.gov
Symptoms
Not everyone has every symptom. Many people feel well and are diagnosed after a skin exam, a lung event, or a kidney scan.
Small facial bumps (fibrofolliculomas) on nose/cheeks/forehead/neck that slowly increase over years. Genetic Rare Diseases Center
Skin-colored or white papules on upper chest/back. NCBI
Skin tags (acrochordons) more common than usual. NCBI
Shortness of breath suddenly, sometimes with chest pain — could be pneumothorax. Cancer.gov
Recurrent pneumothorax (more than once) starting in early–mid adulthood. Cancer.gov
Cough or chest tightness during a lung collapse. Cancer.gov
No lung symptoms at all — many people only learn about cysts on a CT scan done for another reason. Genetic Rare Diseases Center
Kidney issues without pain — tumors often cause no symptoms until large. Cancer.gov
Blood in urine (hematuria) if a kidney tumor bleeds. Cancer.gov
Flank pain if a kidney mass stretches the capsule or if there is a kidney stone unrelated to BHD. Cancer.gov
Cosmetic concern due to facial bumps; lesions are benign but can affect self-image. NCBI
Anxiety about collapse risk after one pneumothorax. Cancer.gov
Family members with similar findings (skin bumps, lung collapses, kidney tumors). PubMed
Occasional other tumors reported (e.g., parotid oncocytoma); overall links are still debated. Cancer.gov
Completely silent — some people are diagnosed only through genetic testing after a relative’s results. NCBI
Diagnostic tests
A) Physical examination (at the clinic)
Full skin exam — dermatologist looks for classic fibrofolliculomas/trichodiscomas on face/neck/upper chest and any skin tags. This pattern suggests BHD and guides genetic testing. NCBI
Family history review — who had skin bumps, collapsed lungs, or kidney tumors and at what ages. A clear pattern supports an inherited condition. PubMed
Respiratory exam — listening for reduced breath sounds on one side, which can suggest a pneumothorax that needs urgent imaging. Cancer.gov
Blood pressure and kidney exam — high blood pressure can accompany kidney disease; flank tenderness is uncommon unless large masses are present. Cancer.gov
B) Manual/bedside tests (simple office tools)
Dermatoscopy — a handheld scope helps visualize skin papules better and choose a spot for biopsy if needed. NCBI
Pulse oximetry — a painless finger sensor checks oxygen level, helpful if a pneumothorax is suspected or during follow-up of lung issues. PMC
Peak flow or simple spirometry — quick breathing tests can document airflow changes if symptoms persist, though many people with BHD have normal lung function between events. Cancer.gov
Bedside ultrasound for pneumothorax (in emergency settings) — trained clinicians can see signs of air outside the lung quickly while preparing for definitive imaging. PMC
C) Laboratory and pathological tests
Genetic testing for FLCN — the key test. A blood or saliva sample is checked for FLCN variants. Finding a pathogenic/likely pathogenic variant confirms BHD. If found in one person, relatives can get targeted testing. NCBI+1
Skin biopsy (if diagnosis is uncertain) — a tiny piece of a papule examined under the microscope shows fibrofolliculoma features. Today, many diagnoses go straight to genetic testing, but biopsy can still help. NCBI
Urinalysis — checks for blood in urine that could signal a kidney mass; not diagnostic by itself but useful for symptoms. Cancer.gov
Basic blood tests (kidney function: creatinine, eGFR) — usually normal early on, but helpful to plan imaging with or without contrast. Cancer.gov
D) Electrodiagnostic / physiologic respiratory tests
Formal spirometry and lung volumes — full pulmonary function testing can document any restriction from large cyst burden; many patients test normal when not having a pneumothorax. Cancer.gov
Diffusing capacity (DLCO) — measures how well oxygen crosses from lungs to blood; may be reduced in some people with large cystic changes. Cancer.gov
Ambulatory oximetry or 6-minute walk — checks oxygen levels and exercise tolerance; helpful if breathlessness persists. PMC
E) Imaging tests (crucial for lungs and kidneys)
High-resolution chest CT (HRCT) — best test to see lung cysts and their pattern (often basilar and subpleural). It helps distinguish BHD from other cystic lung diseases. Cancer.gov
Chest X-ray — fast test to confirm a pneumothorax in an emergency; CT may follow to define size and cyst pattern. Cancer.gov
Kidney MRI (preferred for surveillance) — MRI every 1–2 years starting around age 20 is recommended by international guidelines to catch small tumors early without radiation. Ultrasound is less sensitive; CT finds tumors but adds radiation, so MRI is favored when available. genturis.eu+1
Renal ultrasound — can detect larger or more obvious masses; sometimes used between MRIs or if MRI is not available. Sensitivity is lower for small lesions. PMC
Contrast-enhanced CT or MRI for kidney masses — when a mass is found, contrast imaging helps decide if the tumor needs treatment and aids surgical planning. Cancer.gov
Non-pharmacological (non-drug) treatments — therapies & other measures
Genetic counseling & cascade testing.
Meeting a genetics professional confirms the diagnosis, explains inheritance (autosomal dominant), and helps test at-risk relatives so they can start imaging surveillance early. This improves early tumor detection and family planning. NCBIKidney MRI surveillance (preferred) starting in early adulthood.
Regular MRI (often every 1–2 years; exact cadence individualized) looks for small kidney tumors early. MRI avoids radiation and is more sensitive than ultrasound for BHDS tumors. Early, small tumors allow kidney-sparing treatment. FDA Access Data“3-cm rule” with nephron-sparing intent.
When a renal mass reaches ~3 cm, many centers intervene to protect kidney function while minimizing spread risk; the approach comes from hereditary kidney cancer experience and is widely applied in BHDS care with partial nephrectomy when feasible. FDA Access Data+1Partial nephrectomy (kidney-sparing surgery).
Surgically removing the tumor while preserving kidney tissue controls cancer risk and maintains long-term kidney function—key because people with BHDS may develop more than one tumor over a lifetime. FDA Access DataPercutaneous ablation (e.g., cryoablation/RFA) for select tumors.
For some small tumors in hard-to-reach areas or in people who are poor surgical candidates, image-guided ablation can destroy the tumor with minimal downtime while preserving kidney tissue. FDA Access DataDermatologic laser resurfacing for fibrofolliculomas.
Ablative CO₂ or Er:YAG lasers can flatten many facial bumps and improve appearance; recurrence can occur and more than one session may be needed. These procedures are cosmetic but often boost confidence and quality of life. PMC+1Electrodesiccation/curettage (ED&C) or hyfrecation for skin bumps.
Simple office-based destruction methods can remove multiple lesions quickly. Recurrence can happen; results and downtime vary by technique and operator. Lippincott Journals+1Education on pneumothorax symptoms & action plan.
Because lung cysts raise the risk of sudden lung collapse, patients learn warning signs (sudden chest pain, shortness of breath) and when to seek urgent care. An individualized plan shortens time to treatment. NCBIVATS pleurodesis (with or without bullectomy) for recurrent pneumothorax.
After a recurrent or difficult pneumothorax, minimally invasive surgery that seals the pleural space can reduce recurrences and protect long-term lung function. FDA Access DataActivity counseling about pressure changes (scuba diving/unpressurized flight).
Cystic lungs increase barotrauma risk. Expert consensus advises avoiding scuba and careful planning for air travel, especially soon after a pneumothorax; discuss case-by-case with pulmonology. PMC+1Smoking cessation.
Smoking can worsen lung cyst burden and complications in BHDS; quitting lowers overall lung risks and improves surgical and general health outcomes. FDA Access DataSun protection and gentle skin care.
While fibrofolliculomas are genetic, photoprotection helps overall skin health and cosmetic outcomes after laser or ED&C and may reduce irritation or post-procedure pigment change. MedscapePulmonary rehabilitation/breathing strategies (select cases).
For those with breathlessness after pneumothorax or with many lung cysts, supervised breathing training can support recovery and stamina alongside medical care. ERS PublicationsCardio-renal healthy lifestyle (exercise, BP control, hydration).
General measures that support kidney and vascular health—like blood-pressure control, regular physical activity, and adequate fluid intake—complement medical surveillance. FDA Access DataMedical alert information.
Carrying documentation about BHDS and prior pneumothorax or pleurodesis helps emergency teams act fast if chest symptoms occur during travel or sports. brit-thoracic.org.ukPsychological support & peer networks.
Living with a rare condition can feel isolating. Counseling and patient organizations (e.g., BHD Foundation) provide coping tools and practical guidance. thebhdfoundation.orgCare coordination in a multidisciplinary clinic.
Combining dermatology, pulmonology, urology, radiology, genetics, and primary care leads to better, safer decisions across a lifetime. FDA Access DataImaging choice optimization (MRI over CT when possible).
MRI helps avoid repeated radiation exposure in lifelong surveillance and is more sensitive than ultrasound for BHDS-type tumors. FDA Access DataEarly evaluation of hematuria or flank pain.
New blood in urine or deep back/flank pain needs prompt imaging to rule out a renal mass or bleeding cyst. NCBIPersonalized follow-up schedule.
Intervals for kidney imaging and lung review should be individualized by age, findings, family history, and prior tumors or pneumothorax. FDA Access Data
Drug treatments
Important upfront note: No medicine is approved to cure BHDS itself. The drugs below are evidence-based options for kidney cancers that can occur in BHDS. They are FDA-approved for renal cell carcinoma (RCC) (various lines/settings), not specifically for “BHDS.” Doctors select among them based on tumor type, spread, prior therapy, and the most current guidelines. Always review the full FDA label and use under specialist care.
Sunitinib (SUTENT) — oral multi-targeted TKI.
Used for advanced RCC. Typical dosing is 50 mg once daily for 4 weeks on/2 off (or alternative schedules). It blocks VEGF and other kinases to starve tumors of blood supply. Common effects include fatigue, diarrhea, hand-foot syndrome, and hypertension; labs and blood pressure are monitored. FDA Access DataPazopanib (VOTRIENT) — oral TKI.
Indicated for advanced RCC. Usual dose 800 mg once daily on empty stomach. It inhibits VEGFR, PDGFR, and c-KIT, slowing tumor angiogenesis. Liver tests and blood pressure monitoring are required; diarrhea and hair color change may occur. FDA Access DataAxitinib (INLYTA) — oral TKI.
Used in advanced RCC, often after prior therapy or in combinations. Typical start 5 mg twice daily, titrated by tolerance. It targets VEGFR-1/2/3; side effects include hypertension, fatigue, and diarrhea. FDA Access DataCabozantinib (CABOMETYX) — oral TKI (MET/VEGFR/AXL).
Approved for advanced RCC in several settings and in combinations. Dosing commonly 60 mg once daily (adjust per regimen). It inhibits pro-growth signaling and tumor vasculature; monitor for diarrhea, HFS, mucositis, and hypertension. FDA Access DataTivozanib (FOTIVDA) — oral TKI.
For relapsed/refractory RCC. Dose is 1.34 mg once daily for 21 days on/7 off. It selectively inhibits VEGFR-1/2/3, reducing angiogenesis; hypertension and fatigue are common. PubMedSorafenib (NEXAVAR) — oral TKI.
An older RCC option; dose 400 mg twice daily. It blocks RAF and VEGFR pathways, limiting tumor growth and blood supply; watch for rash, HFS, and hypertension. PLOSTemsirolimus (TORISEL) — IV mTOR inhibitor.
Used for advanced RCC (especially poor-risk). Dose 25 mg IV weekly; it inhibits mTOR to slow tumor cell growth. Monitor glucose, lipids, and for mouth sores and infections. PMCEverolimus (AFINITOR) — oral mTOR inhibitor.
For RCC after failure of certain TKIs. Typical 10 mg once daily; it dampens mTOR signaling; stomatitis, infections, and metabolic changes are watched closely. ClinicalTrials.govBevacizumab (AVASTIN) + interferon-α — anti-VEGF antibody combo (legacy option).
IV bevacizumab plus SC interferon was an early effective regimen for metastatic RCC by starving tumors of blood supply; now less used as newer regimens dominate. Hypertension and bleeding risk are monitored. ResearchGateAldesleukin (PROLEUKIN; high-dose IL-2) — IV cytokine immunotherapy (select centers).
For metastatic RCC in very fit patients, high-dose IL-2 can produce rare durable remissions but has significant toxicity and must be given in ICU-capable settings. FDA Access DataNivolumab (OPDIVO) — PD-1 inhibitor (IV).
Effective in previously treated RCC and in combinations first-line. Dosing regimens vary (e.g., 240 mg Q2W or 480 mg Q4W), unleashing T-cell attack on cancer; immune-related side effects (thyroiditis, colitis, hepatitis) need expert management. FDA Access DataPembrolizumab (KEYTRUDA) — PD-1 inhibitor (IV).
Used alone or in combos (e.g., with axitinib or lenvatinib) as first-line options for advanced RCC. Typical dosing 200 mg Q3W or 400 mg Q6W; monitor for immune-related events. FDA Access DataIpilimumab (YERVOY) + Nivolumab — CTLA-4 + PD-1 combo (IV).
A standard first-line immunotherapy combination for intermediate/poor-risk RCC. Induction ipilimumab with nivolumab followed by nivolumab maintenance can produce durable responses; immune toxicities require experience. PLOSAvelumab (BAVENCIO) + Axitinib — PD-L1 inhibitor + TKI.
A first-line RCC option combining immune activation with anti-angiogenesis. IV avelumab 10 mg/kg Q2W plus oral axitinib; monitor BP, liver tests, and immune-related AEs. FDA Access DataPembrolizumab + Axitinib — PD-1 inhibitor + TKI.
Well-studied first-line combo improving survival across risk groups; immune and vascular side effects require coordinated monitoring. FDA Access DataPembrolizumab + Lenvatinib — PD-1 inhibitor + multi-target TKI.
Another potent first-line combination; lenvatinib dosing is 20 mg daily with pembrolizumab; watch for hypertension, proteinuria, diarrhea, and immune AEs. jaadcasereports.orgNivolumab + Cabozantinib — PD-1 inhibitor + TKI.
A common first-line regimen that pairs immune checkpoint blockade with MET/VEGFR inhibition to control tumor growth and spread. FDA Access DataLenvatinib + Everolimus — TKI + mTOR inhibitor.
Indicated after prior anti-angiogenic therapy; lenvatinib 18 mg daily plus everolimus 5 mg daily balances anti-angiogenic and growth-signal blockade. jaadcasereports.orgTivozanib (as later-line choice).
After multiple prior regimens, tivozanib can offer disease control with a distinct side-effect profile; BP control remains important. PubMedBelzutifan (WELIREG) — oral HIF-2α inhibitor.
Approved for VHL-disease–associated RCC and certain RCC settings; it targets hypoxia-driven genes. While not BHDS-specific, it’s relevant in hereditary kidney-tumor care. Monitor for anemia and hypoxia. U.S. Food and Drug Administration
Clinical reality for BHDS: most BHDS-related renal tumors are treated locally (surgery/ablation) and do not need systemic drugs unless they are advanced or metastatic. Choice of drug depends on tumor histology and guideline-based RCC care. FDA Access Data
Dietary molecular supplements
There is no supplement proven to treat or prevent BHDS. Discuss each with your clinician for safety and interactions.
Vitamin D (dose individualized to blood level).
Supports bone, muscle, and immune function; deficiency is common. Excess causes high calcium and kidney issues—avoid self-dosing above upper limits without labs. Office of Dietary SupplementsOmega-3 (EPA/DHA) from fish oil or diet.
May support cardiometabolic health and lower triglycerides; can raise bleeding risk at high doses and interact with meds—use evidence-based doses. Office of Dietary SupplementsSelenium (trace mineral).
Essential for antioxidant enzymes and thyroid; too much is toxic (hair/nail changes, GI upset). Get baseline intake from diet before considering pills. Office of Dietary SupplementsCoenzyme Q10.
A mitochondrial cofactor sometimes used for statin-associated myalgias; not FDA-approved for disease treatment; generally well tolerated but can interact with anticoagulants. NCBITurmeric/Curcumin.
Anti-inflammatory properties in lab studies; supplement forms may interact with drugs and aren’t recommended in pregnancy; stick to food-level intake unless doctor advises. NCCIH+1Magnesium (diet first).
Supports muscle/nerve and blood pressure; excess from pills can cause diarrhea or interact with certain meds—tailor to need. Office of Dietary SupplementsVitamin B-complex (needs-based).
Useful if a documented deficiency exists; otherwise avoid high-dose chronic use (e.g., high B6 can cause neuropathy). Office of Dietary SupplementsProbiotics (strain-specific).
May help some GI concerns; product quality varies and immunocompromised patients should be cautious—discuss first. Office of Dietary SupplementsVitamin C (diet-priority).
Antioxidant roles; high-dose supplementation isn’t proven to prevent cancer and may cause GI upset or kidney stones in susceptible people. Office of Dietary SupplementsZinc (short-term only if deficient).
Supports immune enzymes; excess long-term zinc can cause copper deficiency and neuropathy—avoid routine high doses. Office of Dietary Supplements
Immunity booster / regenerative / stem-cell drugs
There are no approved immune-booster, regenerative, or stem-cell drugs for BHDS. FDA specifically warns that most stem-cell products marketed to patients are unapproved and potentially dangerous; the only FDA-approved stem-cell products are umbilical-cord blood–derived hematopoietic cells for certain blood disorders, not for BHDS. Avoid clinics offering “stem cells” or “exosomes” for lung, skin, or kidney problems outside regulated trials. Ask your care team about legitimate clinical trials instead. U.S. Food and Drug Administration+1
Bottom line: For BHDS, stick to surveillance, surgery/ablation when needed, pneumothorax prevention/management, and standard RCC therapies if metastatic—not unapproved “stem-cell” interventions. FDA Access Data
Surgeries — procedures & why they’re done
Partial nephrectomy (nephron-sparing).
Removes the tumor while keeping as much kidney as possible—ideal for hereditary syndromes with multiple tumors over time. Often applied around the 3 cm threshold. FDA Access Data+1
Percutaneous cryoablation or radiofrequency ablation.
Freezes or heats the tumor through a needle under imaging—useful for small renal masses or patients unfit for surgery. FDA Access Data
VATS pleurodesis (± bullectomy).
Prevents recurrent pneumothorax by sealing the lung’s outer lining; recommended after recurrent or severe episodes. FDA Access Data
Dermatologic laser ablation (CO₂ / Er:YAG).
Flattens many facial fibrofolliculomas for cosmetic relief; recurrences can occur; multiple sessions may be needed. PMC
Surgical excision/ED&C of select lesions.
Targeted removal of bothersome or large skin lesions when laser isn’t suitable or for diagnostic confirmation. Lippincott Journals
Prevention tips
Keep regular kidney MRI surveillance and follow your personalized schedule. FDA Access Data
Don’t smoke; it worsens lung risk. FDA Access Data
Discuss flying after pneumothorax—usually after full radiographic resolution; timing is individualized. brit-thoracic.org.uk
Avoid scuba diving (especially with lung cysts or prior pneumothorax). PMC
Know pneumothorax symptoms and seek urgent care if they appear. NCBI
Protect skin (SPF, hats) and follow post-procedure care after laser/ED&C. Medscape
Control blood pressure and keep a heart-healthy lifestyle to protect kidneys. FDA Access Data
Share a BHDS care letter (medical alert) before anesthesia or emergency care. brit-thoracic.org.uk
Genetic counseling for family members so they can start surveillance on time. NCBI
Avoid unapproved “stem-cell” treatments. U.S. Food and Drug Administration
When to see a doctor
Right away / emergency: sudden chest pain or shortness of breath (possible pneumothorax), severe flank pain with vomiting, heavy blood in urine, or fainting/weakness. These can be urgent complications. NCBI
Soon (within days): new or growing kidney mass on imaging, persistent mild hematuria, or recovery follow-up after a pneumothorax to plan prevention (e.g., pleurodesis). FDA Access Data
Routine: scheduled MRI kidneys, dermatology check if skin bumps bother you, and periodic pulmonology review if you’ve had a pneumothorax or have many lung cysts. FDA Access Data
What to eat & what to avoid
Overall: a balanced, plant-forward pattern (vegetables, fruits, whole grains, legumes, nuts, fish) is kidney- and heart-friendly. Keep healthy body weight. FDA Access Data
Hydrate regularly unless your clinician limits fluids. Adequate fluids support kidney health. FDA Access Data
Limit salt to support blood pressure control and kidney protection. FDA Access Data
Prefer oily fish 1–2×/week for natural omega-3s (instead of routine high-dose fish-oil pills). Office of Dietary Supplements
Meet, don’t exceed, vitamin D needs; test before supplementing high doses. Office of Dietary Supplements
Be cautious with supplements; “more” is not better (e.g., excess selenium or zinc can harm). Office of Dietary Supplements+1
Avoid smoking and limit alcohol; both harm overall kidney and lung health. FDA Access Data
After skin procedures, follow your dermatologist’s diet/skin-care guidance to reduce pigment changes (e.g., avoid irritants, ensure protein/iron sufficiency). Medscape
If on TKIs or immunotherapy, ask about grapefruit and St. John’s wort interactions; avoid unless cleared. (See each FDA label.) FDA Access Data
Tailor nutrition if you develop chronic kidney disease—work with a renal dietitian for protein, potassium, and phosphorus targets. FDA Access Data
Frequently asked questions (FAQs)
1) Is BHDS cancer?
No. BHDS is a genetic syndrome that raises the risk of certain kidney tumors and causes benign skin and lung findings. Surveillance and early treatment manage these risks. NCBI
2) When should kidney imaging start and how often?
Typically early adulthood with regular MRI (often every 1–2 years), but the schedule is individualized by your team. FDA Access Data
3) Why MRI instead of CT or ultrasound?
MRI avoids radiation and detects the BHDS tumor spectrum better than ultrasound. FDA Access Data
4) What kidney tumors occur in BHDS?
Common patterns include chromophobe RCC, oncocytoma, and hybrid oncocytic/chromophobe tumors; clear-cell RCC is less typical but can occur. AJRCCM
5) What is the “3 cm rule”?
Many hereditary kidney cancer programs consider intervention around 3 cm to balance safety and kidney preservation. auo.asmepress.com
6) Can I scuba dive?
Because lung cysts raise barotrauma risk, experts generally advise against scuba unless a specialized dive medicine and pulmonology evaluation says it’s safe (often not). PMC
7) Can I fly?
Yes—but not soon after a pneumothorax; wait for full radiographic resolution and get individualized advice from your pulmonologist. brit-thoracic.org.uk
8) Are there pills that treat BHDS itself?
No. Drugs treat RCC if it develops; BHDS care relies on surveillance, surgery/ablation, and pneumothorax prevention/management. FDA Access Data
9) Do topical treatments shrink fibrofolliculomas?
A randomized trial of topical rapamycin did not show benefit; lasers/ED&C remain the main cosmetic options, though recurrence can occur. JAMA Network
10) Will I definitely get kidney cancer?
Risk is increased but not 100%. Consistent imaging and timely intervention keep outcomes favorable. NCBI
11) Should my family be tested?
Yes—first-degree relatives should be offered genetic counseling/testing so they can start surveillance if positive. NCBI
12) What causes sudden chest pain in BHDS?
Often a pneumothorax from ruptured lung cysts. It’s an emergency—seek immediate care. NCBI
13) Are stem-cell therapies helpful for BHDS?
No approved stem-cell therapies for BHDS exist; FDA warns against unapproved “regenerative” products. U.S. Food and Drug Administration
14) What if my kidney tumor spreads?
Your oncologist will use RCC-approved drugs (immunotherapy, TKIs, or combinations) based on the tumor and prior treatments. FDA Access Data
15) Where can I find expert guidelines?
See GeneReviews (comprehensive overview) and the ERN GENTURIS 2024 clinical practice guideline for BHDS. NCBI+1
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: October 27, 2025.
